| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000003448 |
| Receipt No. | R000004172 |
| Official scientific title of the study | Effects of Helicobacter pylori eradication therapy on ulcer healing after gastric endoscopic submucosal dissection: a prospective randomized controlled trial. |
| Date of disclosure of the study information | 2010/04/06 |
| Last modified on | 2016/04/05 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Effects of Helicobacter pylori eradication therapy on ulcer healing after gastric endoscopic submucosal dissection: a prospective randomized controlled trial. | |
| Title of the study (Brief title) | Effects of eradication on gastric ESD | |
| Region |
|
|
| Condition | ||
| Condition | Gastric cancer and gastric adenoma | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the benefit of H. pylori eradication before ESD to promote ulcer healing after the procedure. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | state of ulcer healing on 28 days |
| Key secondary outcomes | bleeding after ESD |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | |
| Blinding | Open -but assessor(s) are blinded |
| Control | No treatment |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Helicobacter pylori eradication before gastric ESD
PPI-based triple therapy consisting of lansoprazole (60 mg), amoxicillin (1500 mg) and clarithromycin (400 mg) |
|
| Interventions/Control_2 | Helicobacter pylori eradication after gastric ESD | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Helicobacter pylori positive-patients with gastric cancer or gastric adenoma
1. Not less than 20 years old (no upper limit) 2.Written informed consent |
|||
| Key exclusion criteria | 1)using PPIs and H2RAs
2)using anti-coagulants 3)allergy to drugs 4)severe liver dysfunction 5)severe renal dysfunction 6)Pregnant or lactating women or women |
|||
| Target sample size | 150 | |||
| Research contact person | |
| Name of lead principal investigator | Shouko Ono |
| Organization | Hokkaido University Hospital |
| Division name | Division of Endoscopy |
| Address | Kita-14, Nishi-5, Kita-ku, Sapporo, Japan |
| TEL | 011-716-1161 |
| onosho@med.hokudai.ac.jp | |
| Public contact | |
| Name of contact person | Shouko Ono |
| Organization | Hokkaido University Hospital |
| Division name | Division of Endoscopy |
| Address | N-14, W-5, Kita-ku, Sapporo |
| TEL | 011-716-1161(5723) |
| Homepage URL | |
| onosho@med.hokudai.ac.jp | |
| Sponsor | |
| Institute | Division of Endoscopy, Hokkaido University Hospital |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 北海道大学病院 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-bin/icdr_e/ctr_view.cgi?recptno=R000004172 |